Frederic Pouliot
Overview
Explore the profile of Frederic Pouliot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
3645
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shrem N, Beltran-Bless A, Ghosh S, Tajzler C, Wood L, Kollmannsberger C, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941888
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium...
2.
Soytas M, Dragomir A, Sawaya G, Hesswani C, Tanguay M, Finelli A, et al.
BJU Int
. 2024 Dec;
PMID: 39631366
Objective: To evaluate and compare the outcomes of patients with localised renal cell carcinoma (RCC) with and without sarcomatoid features and the impact of this on cancer recurrence and survival....
3.
Robert A, Mallick R, McIsaac D, Lavallee L, Bhindi B, Heng D, et al.
J Urol
. 2024 Dec;
213(4):455-466.
PMID: 39622017
Purpose: Postoperative prognostic tools allow for improved prediction of future recurrence risk, patient counseling, assessment of eligibility for adjuvant treatments, and appropriate follow-up surveillance. The purpose of this analysis was...
4.
Larose M, Archambault L, Touma N, Brodeur R, Desroches F, Raymond N, et al.
Sci Rep
. 2024 Nov;
14(1):26928.
PMID: 39505979
We propose a fully automatic multi-task Bayesian model, named Bayesian Sequential Network (BSN), for predicting high-grade (Gleason 8) prostate cancer (PCa) prognosis using pre-prostatectomy FDG-PET/CT images and clinical data. BSN...
5.
Pouliot F, Saad F, Rousseau E, Richard P, Zamanian A, Probst S, et al.
J Nucl Med
. 2024 Sep;
65(11):1710-1717.
PMID: 39327017
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to...
6.
Park C, Moria F, Ghosh S, Wood L, Bjarnason G, Bhindi B, et al.
Curr Oncol
. 2024 Aug;
31(8):4704-4712.
PMID: 39195334
Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with...
7.
8.
Jobin C, Harvey M, Lacouture A, Weidmann C, Neveu B, Pouliot F, et al.
STAR Protoc
. 2024 Jul;
5(3):103200.
PMID: 39028619
Patient-derived organoids (PDOs) are now used to study many diseases, including prostate cancer. Here, we present a protocol for the transduction of human epithelial prostate cells and PDOs. We describe...
9.
Galey L, Olanrewaju A, Nabi H, Paquette J, Pouliot F, Audet-Walsh E
J Steroid Biochem Mol Biol
. 2024 Jul;
243:106588.
PMID: 39025336
The prevailing biomarker employed for prostate cancer (PCa) screening and diagnosis is the prostate-specific antigen (PSA). Despite excellent sensitivity, PSA lacks specificity, leading to false positives, unnecessary biopsies and overdiagnosis....
10.
Galey L, Olanrewaju A, Nabi H, Paquette J, Pouliot F, Audet-Walsh E
Nat Rev Urol
. 2024 May;
21(10):573-575.
PMID: 38811764
No abstract available.